Literature DB >> 19711646

Computed tomography in metastatic renal cell carcinoma.

Nyree Griffin1, Lee Alexander Grant, Nishat Bharwani, S Aslam Sohaib.   

Abstract

Recent developments in chemotherapy have resulted in several new drug treatments for metastatic renal cell carcinoma (RCC). These therapies have shown improved progression-free survival and are applicable to many more patients than the conventional cytokine-based treatments for metastatic RCC. Consequently imaging is playing a greater part in the management of such patients. Computed tomography (CT) remains the primary imaging modality with other imaging modalities playing a supplementary role. CT is used in the diagnosis and staging of metastatic RCC. It is used in the follow-up of patients after nephrectomy, in assessing the extent of metastatic disease, and in evaluating response to treatment. This review looks at the role of CT in patients with metastatic RCC and describes the appearances of metastatic RCC before and following systemic therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19711646     DOI: 10.1053/j.sult.2009.03.007

Source DB:  PubMed          Journal:  Semin Ultrasound CT MR        ISSN: 0887-2171            Impact factor:   1.875


  3 in total

1.  Omental Nodular Deposits of Recurrent Chromophobe Renal Cell Carcinoma Seen on FDG-PET/CT.

Authors:  Aung Zaw Win; Carina Mari Aparici
Journal:  J Clin Imaging Sci       Date:  2014-09-23

2.  Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma.

Authors:  N Bharwani; M E Miquel; T Powles; P Dilks; A Shawyer; A Sahdev; P D Wilson; S Chowdhury; D M Berney; A G Rockall
Journal:  Br J Cancer       Date:  2013-12-24       Impact factor: 7.640

3.  Surgical challenges in the treatment of a giant renal cell carcinoma with atypical presentation: A case report.

Authors:  Rodolfo J Oviedo; Jarrod C Robertson; Kenneth Whithaus
Journal:  Int J Surg Case Rep       Date:  2016-05-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.